Clinical Trial Update: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 1/2 study of erlotinib hydrochloride combined with onalespib lactate in patients with recurrent or metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)
• Onalespib lactate (Onalespib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7 | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-06-22